Cresset Asset Management’s GSK GSK Stock Holding History

Cresset Asset Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.28M	Sell	24,149 -2,893	-11%	-$153K	﹤0.01%	814
2026 Q1	$1.5M	Buy	27,042 +2,210	+9%	+$120K	0.01%	639
2025 Q4	$1.23M	Buy	24,832 +11,585	+87%	+$540K	0.01%	722
2025 Q3	$578K	Buy	13,247 +101	+0.8%	+$3.94K	﹤0.01%	959
2025 Q2	$511K	Sell	13,146 -5,851	-31%	-$224K	﹤0.01%	922
2025 Q1	$743K	Sell	18,997 -1,695	-8%	-$62.1K	﹤0.01%	893
2024 Q4	$707K	Sell	20,692 -41,175	-67%	-$1.48M	﹤0.01%	936
2024 Q3	$2.55M	Buy	61,867 +7,527	+14%	+$308K	0.01%	685
2024 Q2	$2.11M	Buy	54,340 +25,040	+85%	+$1.05M	0.01%	701
2024 Q1	$1.27M	Sell	29,300 -1,001	-3%	-$41.3K	0.01%	876
2023 Q4	$1.13M	Buy	30,301 +5,352	+21%	+$192K	0.01%	842
2023 Q3	$912K	Buy	24,949 +375	+2%	+$13.3K	﹤0.01%	899
2023 Q2	$884K	Buy	+24,574	New	+$881K	﹤0.01%	1000
2022 Q3	–	Sell	-6,098	Closed	-$334K	–	917
2022 Q2	$334K	Sell	6,098 -908	-13%	-$50.1K	﹤0.01%	679
2022 Q1	$386K	Sell	7,006 -390	-5%	-$21.2K	﹤0.01%	683
2021 Q4	$412K	Buy	7,396 +101	+1%	+$5.25K	﹤0.01%	759
2021 Q3	$353K	Buy	7,295 +2,557	+54%	+$128K	﹤0.01%	775
2021 Q2	$239K	Sell	4,738 -2,701	-36%	-$130K	﹤0.01%	877
2021 Q1	$332K	Buy	7,439 +300	+4%	+$13.6K	0.01%	631
2020 Q4	$333K	Sell	7,139 -2,354	-25%	-$108K	0.01%	526
2020 Q3	$453K	Sell	9,493 -2,109	-18%	-$106K	0.01%	395
2020 Q2	$601K	Buy	11,602 +6,443	+125%	+$331K	0.01%	305
2020 Q1	$252K	Sell	5,159 -5,672	-52%	-$303K	0.01%	446
2019 Q4	$643K	Buy	10,831 +140	+1%	+$7.79K	0.02%	264
2019 Q3	$576K	Buy	+10,691	New	+$550K	0.02%	246
2019 Q2	–	Sell	-6,056	Closed	-$321K	–	950
2019 Q1	$321K	Buy	6,056 +2,766	+84%	+$138K	0.01%	252
2018 Q4	$159K	Buy	+3,290	New	+$162K	0.01%	251

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Cresset Asset Management's GSK Position: Q2 2026 in Review

Cresset Asset Management reduced its GSK (GSK) stake by 11% in Q2 2026, selling an estimated $153K and leaving 24,149 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #814.

Cresset Asset Management first reported a position in GSK in Q4 2018 and has held it in 27 quarters since. The position peaked at $2.55M in Q3 2024. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Cresset Asset Management held 24,149 shares of GSK worth $1.28M as of Q2 2026.
Cresset Asset Management sold 2,893 GSK shares in Q2 2026, an estimated $153K.
GSK made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #814 holding.
Cresset Asset Management first reported a position in GSK in Q4 2018 and has held it in 27 quarters since.
Cresset Asset Management's GSK position peaked at $2.55M in Q3 2024.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.